

CPC COOPERATIVE PATENT CLASSIFICATION

C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS ([immunoassay G01N 33/53](#)); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

NOTES

1. This subclass does not cover the observation of the progress or of the result of processes specified in this subclass by any of the methods specified in groups [G01N 3/00](#) - [G01N 29/00](#), which is covered by subclass [G01N](#).
2. In this subclass, the following expression is used with the meaning indicated:
"involving", when used in relation to a substance, includes the testing for the substance as well as employing the substance as a determinant or reactant in a test for a different substance.
3. Attention is drawn to Notes (1) to (3) following the title of class [C12](#).
4. In this subclass, test media are classified in the appropriate group for the relevant test process.
5. Documents describing the use of an electrode for analysis of a specific analyte are classified in [C12Q 1/001](#) or subgroups and not according to the last place rule
6. Documents relating to new peptides, e.g. enzymes, or new DNA or its corresponding mRNA, encoding for the peptides, and their use in measuring or testing processes are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their use in diagnostics. However where the new nucleic acids are principally used in diagnostic processes, e.g. PCR, hybridisation reactions, the documents are also classified in group [C12Q 1/68](#)
7. When classifying in groups [C12Q 1/68](#) - [C12Q 1/70](#) it is desirable to classify with symbols from groups [C12Q 2500/00](#) - [C12Q 2565/634](#), relating to relevant technical features of the invention, using Combination Sets.
8. In groups [C12Q 1/6876](#) - [C12Q 1/6895](#) and [C12Q 1/70](#) - [C12Q 1/708](#) it is desirable to add the indexing codes [C12Q 2600/00](#) - [C12Q 2600/178](#) which reflect the use of the product in combination with the virus groups only if the application refers to products.

1/00	Measuring or testing processes involving enzymes, {nucleic acids} or micro-organisms (measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters C12M 1/34); Compositions therefor; Processes of preparing such compositions	1/16	. . . using radioactive material
		1/18	. . Testing for antimicrobial activity of a material
		1/20	. . . using multifield media
		1/22	. . Testing for sterility conditions
		1/24	. . Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact micro-organisms
1/001	. {Enzyme electrodes}	1/25	. involving enzymes not classifiable in groups C12Q 1/26 {- C12Q 1/66 }
1/002	. . {Electrode membranes}	1/26	. involving oxidoreductase
1/003	. . . {Functionalisation}	1/28	. . involving peroxidase
1/004	. . {mediator-assisted}	1/30	. . involving catalase
1/005	. . {involving specific analytes or enzymes (including groups of enzymes, e.g. oxydases; C12Q 1/004 takes precedence)}	1/32	. . involving dehydrogenase
1/006	. . . {for glucose}	1/34	. involving hydrolase
1/007	. {involving isoenzyme profiles (for detection of an individual isoenzyme C12Q 1/25 - C12Q 1/66)}	1/37	. . involving peptidase or proteinase
1/008	. {for determining co-enzymes or co-factors, e.g. NAD, ATP}	1/40	. . involving amylase
1/02	. involving viable micro-organisms	1/42	. . involving phosphatase
1/025	. . {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q 1/18)}	1/44	. . involving esterase
1/04	. . Determining presence or kind of micro-organism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q 1/6897 takes precedence)}	1/46	. . . involving cholinesterase
		1/48	. involving transferase
		1/485	. . {involving kinase}
		1/50	. . involving creatine phosphokinase
		1/52	. . involving transaminase
		1/527	. involving lyase
		1/533	. involving isomerase
1/045	. . . {Culture media therefor}	1/54	. involving glucose or galactose
1/06	. . . Quantitative determination	1/56	. involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
1/08 using multifield media	1/58	. involving urea or urease
1/10	. . . Enterobacteria	1/60	. involving cholesterol
1/12	. . . Nitrate to nitrite reducing bacteria	1/61	. involving triglycerides
1/14	. . . Streptococcus; Staphylococcus	1/62	. involving uric acid

- 1/64 . Geomicrobiological testing, e.g. for petroleum
- 1/66 . involving luciferase
- 1/68 . involving nucleic acids

NOTE

In subgroups of [C12Q 1/68](#), classification is made according to the most relevant feature rather than according to the last-place-rule

- 1/6802 . . {General aspects (not used, see subgroups)}
- 1/6804 . . . {Nucleic acid analysis utilising immunogens}
- 1/6806 . . . {Preparing nucleic acids for analysis, e.g. for PCR assay ([C12Q 1/6804](#) takes precedence)}
- 1/6809 . . . {Sequence identification involving differential detection}
- 1/6811 . . . {Selection methods for production or design of target specific oligonucleotide or binding molecules}
- 1/6813 . . {Hybridisation assays}
- 1/6816 . . . {characterised by the means of detection ([C12Q 1/6804](#) takes precedence)}
- 1/6818 {involving interaction of at least two labels, e.g. resonant energy transfer}
- 1/682 {Signal amplification}
- 1/6823 {Release of bound marker}
- 1/6825 {Nucleic acid detection involving sensors}
- 1/6827 . . . {for mutation or polymorphism detection}
- 1/683 {involving restriction enzymes, e.g. RFLP}
- 1/6832 . . . {Enhancement of hybridisation reaction}
- 1/6834 . . . {Nucleic acid analysis involving immobilisation; Immobilisation characterised by the carrier or coupling agent}
- 1/6837 {characterised by the use of probe arrays or probe chips ([C12Q 1/6874](#) takes precedence)}
- 1/6839 . . . {Triple helix formation in hybridisation assays}
- 1/6841 . . . {"In-situ" hybridisation}
- 1/6844 . . {Nucleic acid amplification reactions}
- 1/6846 . . . {Common amplification features}
- 1/6848 {preventing contamination}
- 1/6851 {Quantitative amplification}
- 1/6853 {using modified primers or templates}
- 1/6855 {Ligating adaptors}
- 1/6858 {Allele specific amplification}
- 1/686 . . . {Polymerase Chain Reaction [PCR]}
- 1/6862 . . . {Ligase Chain Reaction [LCR]}
- 1/6865 . . . {Promoter based amplification, e.g. NASBA, 3SR, TAS}
- 1/6867 . . . {Replicase based amplifications, e.g. Q-beta replicase}
- 1/6869 . . {Methods for sequencing}
- 1/6872 . . . {involving mass spectrometry}
- 1/6874 . . . {involving nucleic acid arrays, e.g. Sequencing By Hybridisation [SBH]}
- 1/6876 . . {Hybridisation probes}
- 1/6879 . . . {for sex determination}
- 1/6881 . . . {for tissue and cell typing, e.g. HLA probes}
- 1/6883 . . . {for diseases caused by alterations of genetic material}
- 1/6886 {for cancer}
- 1/6888 . . . {for detection or identification of organisms}
- 1/689 {for bacteria}
- 1/6893 {for protozoa}

- 1/6895 {for plants, fungi, or algae}
- 1/6897 . . {involving reporter genes operably linked to promoters}
- 1/70 . involving virus or bacteriophage
- 1/701 . . {Specific hybridization probes}
- 1/702 . . . {for retroviruses}
- 1/703 {Viruses associated with AIDS}
- 1/705 . . . {for herpesviridae, e.g. herpes simplex, varicella zoster}
- 1/706 . . . {for hepatitis}
- 1/707 {non-A, non-B Hepatitis, excluding hepatitis D}
- 1/708 . . . {for papilloma}

3/00 **Condition responsive control processes** (apparatus therefor [C12M 1/36](#); controlling or regulating in general [G05](#))

2304/00 **Chemical means of detecting micro-organisms** (hydrolase substrates [C12Q 2334/00](#), peptidase substrates [C12Q 2337/00](#))

- 2304/10 . DNA staining
- 2304/12 . . Ethidium
- 2304/13 . . Propidium
- 2304/16 . . Acridine orange
- 2304/18 . . Thionin-type dyes, e.g. Azure, Toluidine Blue
- 2304/20 . Redox indicators
- 2304/22 . . Resazurin; Resorufin
- 2304/24 . . Tetrazolium; Formazan
- 2304/26 . . Quinone; Quinol
- 2304/40 . Detection of gases
- 2304/44 . . Oxygen
- 2304/46 . . Carbon dioxide
- 2304/48 . . Ammonia or volatile amines
- 2304/60 . Chemiluminescent detection using ATP-luciferin-luciferase system
- 2304/80 . Electrochemical detection via electrodes in contact with culture medium

2326/00 **Chromogens for determinations of oxidoreductase enzymes**

- 2326/10 . Benzidines
- 2326/12 . . 3,3',5,5'-Tetramethylbenzidine, i.e. TMB
- 2326/14 . . Ortho-Tolidine, i.e. 3,3'-dimethyl-(1,1'-biphenyl-4,4'-diamine)
- 2326/20 . Ortho-Phenylenediamine
- 2326/30 . 2,2'-Azinobis (3-ethylbenzothiazoline-6-sulfonic acid), i.e. ABTS
- 2326/32 . 3-Methyl-2-benzothiazolinone hydrazone hydrochloride hydrate, i.e. MBTH
- 2326/40 . Triphenylmethane dye chromogens, e.g. fluorescein derivatives
- 2326/50 . Phenols; Naphthols; Catechols
- 2326/90 . Developer
- 2326/92 . . Nitro blue tetrazolium chloride, i.e. NBT
- 2326/96 . . 4-Amino-antipyrine

2334/00 **O-linked chromogens for determinations of hydrolase enzymes, e.g. glycosidases, phosphatases, esterases**

- 2334/10 . p-Nitrophenol derivatives
- 2334/20 . Coumarin derivatives
- 2334/22 . . 4-Methylumbelliferyl, i.e. beta-methylumbelliferone, 4MU

2334/30	. Naphthol derivatives, e.g. alpha-naphthyl-esters, i.e. alpha-NE, beta-naphthyl-esters, i.e. beta-NE	2522/10	. Nucleic acid binding proteins (not used)
2334/40	. Triphenylmethane dye chromogens, e.g. fluorescein derivatives	2522/101	. . Single or double stranded nucleic acid binding proteins
2334/50	. Indoles	2523/00	Reactions characterised by treatment of reaction samples (not used)
2334/52	. . 5-Bromo-4-chloro-3-indolyl, i.e. BCI	2523/10	. Characterised by chemical treatment (Not used)
2334/70	. the product, e.g. phenol, naphthol being diazotised in situ , e.g. with Fast Red	2523/101	. . Crosslinking agents, e.g. psoralen
2337/00	N-linked chromogens for determinations of peptidases and proteinases	2523/107	. . Chemical cleaving agents
2337/10	. Anilides	2523/109	. . chemical ligation between nucleic acids
2337/12	. . Para-Nitroanilides p-NA	2523/113	. . Denaturing agents
2337/20	. Coumarin derivatives	2523/115	. . oxidising agents
2337/22	. . 7-Amino-4-methylcoumarin, i.e. AMC, MCA	2523/119	. . Renaturing agents
2337/24	. . 7-Amino-4-trifluoromethylcoumarin, i.e. AFC	2523/125	. . Bisulfite(s)
2337/30	. Naphthyl amides, e.g. beta-NA, 2-NA, 4-methoxy-beta-naphthylamine, i.e. 4MNA	2523/30	. Characterised by physical treatment (Not used)
2337/40	. Rhodamine derivatives	2523/301	. . Sonication
2337/50	. Indoles	2523/303	. . Applying a physical force on a nucleic acid
2337/52	. . 5-Bromo-4-chloro-3-indolyl, i.e. BCI	2523/305	. . Denaturation or renaturation by physical action
2500/00	Analytical methods involving nucleic acids (not used)	2523/307	. . Denaturation or renaturation by electric current/voltage
2520/00	Reactions involving nucleic acids (not used)	2523/308	. . Adsorption or desorption
2521/00	Reaction characterised by the enzymatic activity (not used)	2523/31	. . Electrostatic interactions, e.g. use of cationic polymers in hybridisation reactions
2521/10	. Nucleotidyl transferring (not used)	2523/313	. . Irradiation, e.g. UV irradiation
2521/101	. . DNA polymerase	2523/319	. . Photocleavage, photolysis, photoactivation
2521/107	. . RNA dependent DNA polymerase,(i.e. reverse transcriptase)	2523/32	. . Centrifugation
2521/113	. . Telomerase	2525/00	Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
2521/119	. . RNA polymerase	2525/10	. Modifications characterised by
2521/125	. . Methyl transferase, i.e. methylase	2525/101	. . incorporating non-naturally occurring nucleotides, e.g. inosine
2521/131	. . Terminal transferase	2525/107	. . incorporating a peptide nucleic acid
2521/30	. Phosphoric diester hydrolysing, i.e. nuclease (Not used)	2525/113	. . incorporating modified backbone
2521/301	. . Endonuclease	2525/117	. . incorporating modified base
2521/307	. . Single strand endonuclease	2525/119	. . incorporating abasic sites
2521/313	. . Type II endonucleases, i.e. cutting outside recognition site	2525/121	. . incorporating both deoxyribonucleotides and ribonucleotides
2521/319	. . Exonuclease	2525/125	. . incorporating agents resulting in resistance to degradation
2521/325	. . Single stranded exonuclease	2525/131	. . incorporating a restriction site
2521/327	. . RNase, e.g. RNaseH	2525/137	. . incorporating/modifying moieties to eliminate restriction sites
2521/331	. . Methylation site specific nuclease	2525/143	. . incorporating a promoter sequence (Not used with code C12Q 2531/143)
2521/337	. . Ribozyme	2525/149	. . incorporating a coding sequence
2521/343	. . Abzyme	2525/15	. . incorporating a consensus or conserved sequence
2521/345	. . DNAzyme	2525/151	. . repeat or repeated sequences, e.g. VNTR, microsatellite, concatemer
2521/50	. Other enzymatic activities (Not used)	2525/155	. . incorporating/generating a new priming site
2521/501	. . Ligase	2525/161	. . incorporating target specific and non-target specific sites
2521/507	. . Recombinase	2525/173	. . incorporating a polynucleotide run, e.g. polyAs, polyTs
2521/513	. . Winding/unwinding enzyme, e.g. helicase	2525/179	. . incorporating arbitrary or random nucleotide sequences
2521/514	. . Mismatch repair protein	2525/185	. . incorporating base(s) where the precise position of the base(s) in the nucleic acid string is important (Not to be used for 3'-end base)
2521/519	. . Topoisomerase	2525/186	. . incorporating a non-extendable or blocking moiety (not used with C12Q 2535/101)
2521/525	. . Phosphatase (Not used with code C12Q 2565/301)	2525/191	. . incorporating an adaptor
2521/531	. . Glycosylase	2525/197	. . incorporating a spacer/coupling moiety
2521/537	. . Protease		
2521/539	. . Deaminase		
2521/543	. . Immobilised enzyme(s)		
2522/00	Reaction characterised by the use of non-enzymatic proteins (not used)		

2525/203	. . incorporating a composite nucleic acid containing a polypeptide sequence other than PNA	2535/107	. . Maxam and Gilbert method, i.e. sequential release and detection of nucleotides
2525/204	. . specific length of the oligonucleotides	2535/113	. . Cycle sequencing
2525/205	. . Aptamer	2535/119	. . Double strand sequencing
2525/207	. . siRNA, miRNA	2535/122	. . Massive parallel sequencing
2525/30	. Oligonucleotides characterised by their secondary structure	2535/125	. . Allele specific primer extension
2525/301	. . Hairpin oligonucleotides	2535/131	. . Allele specific probes
2525/307	. . Circular oligonucleotides	2535/137	. . Amplification Refractory Mutation System [ARMS]
2525/313	. . Branched oligonucleotides	2535/138	. . Amplified fragment length polymorphism [AFLP]
2527/00	Reactions demanding special reaction conditions (not used)	2535/139	. . Random amplification polymorphism detection [RAPD] (not to be used with C12Q 2525/179)
2527/10	. Reaction conditions characterised by (metal/ion C12Q 2563/137) (not used)	2537/00	{Reactions characterised by the reaction format or use of a specific feature}
2527/101	. . Temperature	2537/10	. the purpose or use of
2527/107	. . Temperature of melting, i.e. T _m	2537/101	. . Homogeneous assay format, e.g. one pot reaction
2527/109	. . Pressure	2537/107	. . Homoduplex formation
2527/113	. . Time	2537/113	. . Heteroduplex formation
2527/119	. . pH	2537/119	. . Triple helix formation
2527/125	. . Specific component of sample, medium or buffer (for metal/ion use C12Q 2563/137)	2537/125	. . Sandwich assay format
2527/127	. . the enzyme inhibitor or activator used	2537/137	. . a displacement step (Not used with code C12Q 2531/119)
2527/137	. . Concentration of a component of medium	2537/1373	. . . Displacement by a nucleic acid
2527/143	. . Concentration of primer/probe	2537/1376	. . . Displacement by an enzyme
2527/146	. . Concentration of target/template	2537/143	. . Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
2527/149	. . Concentration of an enzyme	2537/149	. . Sequential reactions (Not used with reactions implicitly known to be sequential, e.g. amplification reactions)
2527/15	. . Gradients	2537/155	. . Cyclic reactions (Not used with codes C12Q 2531/101 - C12Q 2531/149)
2527/153	. . Viscosity	2537/157	. . A reaction step characterised by the number of molecules incorporated or released
2527/156	. . Permeability	2537/159	. . Reduction of complexity, e.g. amplification of subsets, removing duplicated genomic regions
2531/00	Reactions of nucleic acids characterised by	2537/16	. . Assays for determining copy number or wherein the copy number is of special importance
2531/10	. the purpose being amplify/increase the copy number of target nucleic acid (Not used)	2537/161	. . A competitive reaction step (Not used with code C12Q 2545/107)
2531/101	. . Linear amplification, i.e. non exponential	2537/162	. . Helper probe
2531/107	. . Asymmetric PCR	2537/163	. . blocking probe (not used in combination with C12Q 2527/127 or C12Q 2525/186)
2531/113	. . PCR	2537/164	. . Methylation detection other than bisulfite or methylation sensitive restriction endonucleases
2531/119	. . Strand displacement amplification [SDA]	2537/165	. . Mathematical modelling, e.g. logarithm, ratio
2531/125	. . Rolling circle	2539/00	{Reactions characterised by analysis of gene expression or genome comparison}
2531/131	. . Inverse PCR	2539/10	. The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
2531/137	. . Ligase Chain Reaction [LCR]	2539/101	. . Subtraction analysis
2531/143	. . Promoter based amplification, e.g. NASBA, 3SR, TAS	2539/103	. . Serial analysis of gene expression [SAGE]
2531/149	. . Replicase based amplification, e.g. Q beta replicase	2539/105	. . Involving introns, exons, or splice junctions
2533/00	{Reactions characterised by the enzymatic reaction principle used}	2539/107	. . Representational Difference Analysis [RDA]
2533/10	. the purpose being to increase the length of an oligonucleotide strand (ligase detection reaction, LDR C12Q 2561/125)	2539/113	. . Differential Display Analysis [DDA]
2533/101	. . Primer extension (see also codes C12Q 2535/125 , C12Q 2565/537)	2539/115	. . Comparative genomic hybridisation [CGH]
2533/107	. . Probe/oligonucleotide ligation (Not used with code C12Q 2531/137 , C12Q 2561/125)	2541/00	{Reactions characterised by directed evolution}
2535/00	{Reactions characterised by the assay type for determining the identity of a nucleotide base}	2541/10	. the purpose being the selection/design of target specific nucleic acid binding sequences (not used)
2535/10	. the purpose being to determine the identity or sequence oligonucleotides characterised by (Not used)		
2535/101	. . Sanger sequencing method, i.e. oligonucleotide sequencing using primer elongation and dideoxynucleotides as chain terminators		

C12Q

2541/101	. . Selex	2563/119	. the label being proteinic
2543/00	{Reactions characterised by the reaction site, e.g. cell or chromosome}	NOTE	
2543/10	. the purpose being " <u>in situ</u> " analysis	Not to be used with code C12Q 2565/531	
2543/101	. . <u>in situ</u> amplification	2563/125	. the label being enzymatic, i.e. proteins, and non proteins, such as nucleic acid with enzymatic activity
2545/00	{Reactions characterised by their quantitative nature}	NOTE	
2545/10	. the purpose being quantitative analysis (Not used)	This code is restricted in use to ENZYMES as a LABEL	
2545/101	. . with an internal standard/control	2563/131	. the label being a member of a cognate binding pair, i.e. extends to antibodies, haptens, avidin
2545/107	. . with a competitive internal standard/control	2563/137	. Metal/ion, e.g. metal label
2545/113	. . with an external standard/control, i.e. control reaction is separated from the test/target reaction	2563/143	. Magnetism, e.g. magnetic label
2545/114	. . involving a quantitation step (not to be used with C12Q 2545/101 , C12Q 2545/107 , C12Q 2545/113)	2563/149	. Particles, e.g. beads
2547/00	{Reactions characterised by the features used to prevent contamination}	2563/155	. Particles of a defined size, e.g. nanoparticles
2547/10	. the purpose being preventing contamination (Not used)	2563/157	. Nanotubes or nanorods
2547/101	. . by confinement to a single tube/container	2563/159	. Microreactors, e.g. emulsion PCR or sequencing, droplet PCR, microcapsules, i.e. non-liquid containers with a range of different permeability's for different reaction components
2547/107	. . Use of permeable barriers, e.g. waxes	2563/161	. Vesicles, e.g. liposome
2549/00	{Reactions characterised by the features used to influence the efficiency or specificity}	2563/167	. Mass label
2549/10	. the purpose being that of reducing false positive/negative signals (Not used)	2563/173	. staining/intercalating agent, e.g. ethidium bromide
2549/101	. . Hot start	2563/179	. the label being a nucleic acid
2549/107	. . Cold start	2563/185	. Nucleic acid dedicated to use as a hidden marker/bar code, e.g. inclusion of nucleic acids to mark art objects or animals
2549/113	. . using nested probes	2565/00	Nucleic acid analysis characterised by mode or means of detection
2549/119	. . using nested primers	2565/10	. Detection mode being characterised by (Not used)
2549/125	. . using sterilising/blocking agents, e.g. albumin	2565/101	. . Interaction between at least two labels
2549/126	. . using oligonucleotides as clamps (not to be used with C12Q 2525/107)	2565/1015	. . . labels being on the same oligonucleotide
2560/00	Nucleic acid detection (not used)	2565/102	. . Multiple non-interacting labels
2561/00	Nucleic acid detection characterised by assay method (not used)	2565/1025	. . . labels being on the same oligonucleotide
2561/10	. Characterised by assay method (Not used)	2565/107	. . Alteration in the property of hybridised versus free label oligonucleotides
2561/101	. . Taqman	2565/113	. . based on agglutination/precipitation
2561/107	. . Enzyme complementation	2565/119	. . based on extraction of label to an organic phase, i.e. partitioning of label between different organic phases
2561/108	. . Hybridisation protection assay [HPA]	2565/125	. . Electrophoretic separation
2561/109	. . Invader technology	2565/131	. . Single/double strand conformational analysis, i.e. SSCP/DSCP
2561/113	. . Real time assay	2565/133	. . conformational analysis
2561/119	. . Fluorescence polarisation	2565/137	. . Chromatographic separation
2561/12	. . Fluorescence lifetime measurement	2565/20	. Detection means characterised by being a gene reporter based analysis (Not used)
2561/125	. . Ligase Detection Reaction [LDR]	2565/201	. . Two hybrid system
2561/127	. . Protein truncation assay	2565/207	. . Three hybrid system
2563/00	Nucleic acid detection characterised by the use of (not used)	2565/30	. Detection characterised by liberation/release of label (Not used)
2563/101	. radioactivity, e.g. radioactive labels	2565/301	. . Pyrophosphate (PPi)
2563/103	. luminescence	2565/40	. Detection characterised by signal amplification of label (not used)
2563/107	. fluorescence	2565/401	. . Signal amplification by chemical polymerisation
2563/113	. the label being electroactive, e.g. redox labels	2565/50	. Detection characterised by immobilisation to a surface
2563/116	. electrical properties of nucleic acids, e.g. impedance, conductivity or resistance	2565/501	. . being on/an array of oligonucleotides
NOTE		2565/507	. . characterised by the density of the capture oligonucleotide
Not to be used with C12Q 2563/113			

C12Q

- 2565/513 . . characterised by the pattern of the arrayed oligonucleotides
- 2565/514 . . characterised by the use of the arrayed oligonucleotides as identifier tags, e.g. universal addressable array, anti-tag or tag complement array
- 2565/515 . . characterised by the interaction between or sequential use of two or more arrays
- 2565/518 . . characterised by the immobilisation of the nucleic acid sample or target
- 2565/519 . . characterised by the capture moiety being a single stranded oligonucleotide
- 2565/525 . . characterised by the capture oligonucleotide being double stranded
- 2565/531 . . characterised by the capture moiety being a protein for target oligonucleotides
- 2565/537 . . characterised by the capture oligonucleotide acting as a primer
- 2565/543 . . characterised by the use of two or more capture oligonucleotide primers in concert, e.g. bridge amplification (Not used with code [C12Q 2537/149](#))
- 2565/549 . . characterised by the capture oligonucleotide being a reporter labelled capture oligonucleotide
- 2565/60 . Detection means characterised by use of a special device (Not used)
- 2565/601 . . being a microscope, e.g. atomic force microscopy [AFM]
- 2565/607 . . being a sensor, e.g. electrode
- 2565/619 . . being a video camera
- 2565/625 . . being a nucleic acid test strip device, e.g. dipsticks, strips, tapes, CD plates
- 2565/626 . . being a flow cytometer
- 2565/627 . . being a mass spectrometer (not to be used with [C12Q 2563/167](#))
- 2565/628 . . being a surface plasmon resonance spectrometer
- 2565/629 . . being a microfluidic device
- 2565/631 . . being a biochannel or pore
- 2565/632 . . being a surface enhanced, e.g. resonance, Raman spectrometer
- 2565/633 . . NMR
- 2565/634 . . being an acoustic wave sensor
- 2600/00** **Oligonucleotides characterized by their use (not used, see subgroups)**
- 2600/106 . Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- 2600/112 . Disease subtyping, staging or classification
- 2600/118 . Prognosis of disease development
- 2600/124 . Animal traits, i.e. production traits, including athletic performance or the like
- 2600/13 . Plant traits
- 2600/136 . Screening for pharmacological compounds
- 2600/142 . Toxicological screening, e.g. expression profiles which identify toxicity
- 2600/148 . Screening for cosmetic compounds
- 2600/154 . Methylation markers
- 2600/156 . Polymorphic or mutational markers
- 2600/158 . Expression markers
- 2600/16 . Primer sets for multiplex assays
- 2600/166 . Oligonucleotides used as internal standards, controls or normalisation probes
- 2600/172 . Haplotypes
- 2600/178 . miRNA, siRNA or ncRNA